193 related articles for article (PubMed ID: 22314079)
21. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study.
Artini PG; Di Berardino OM; Papini F; Genazzani AD; Simi G; Ruggiero M; Cela V
Gynecol Endocrinol; 2013 Apr; 29(4):375-9. PubMed ID: 23336594
[TBL] [Abstract][Full Text] [Related]
22. [Tyrosine phosphorylation and protein expression of insulin receptor substrate-1 in the patients with polycystic ovary syndrome].
Chu YL; Sun YY; Qiu HY; Li HF
Zhonghua Fu Chan Ke Za Zhi; 2004 Mar; 39(3):176-9. PubMed ID: 15130378
[TBL] [Abstract][Full Text] [Related]
23. Does hyperandrogenism have an effect on hearing loss in patients with polycystic ovary syndrome?
Oghan F; Coksuer H
Auris Nasus Larynx; 2012 Aug; 39(4):365-8. PubMed ID: 21862266
[TBL] [Abstract][Full Text] [Related]
24. Serum calcitonin gene-related peptide levels in women with polycystic ovary syndrome.
Fenkci SM; Fenkci V; Oztekin O; Rota S
Arch Gynecol Obstet; 2013 Jun; 287(6):1235-9. PubMed ID: 23263174
[TBL] [Abstract][Full Text] [Related]
25. Body fat composition and distribution in women with polycystic ovary syndrome.
Cosar E; Uçok K; Akgün L; Köken G; Sahin FK; Arioz DT; Baş O
Gynecol Endocrinol; 2008 Aug; 24(8):428-32. PubMed ID: 18850379
[TBL] [Abstract][Full Text] [Related]
26. Phenotypic expression, body mass index and insulin resistance in relation to LH levels in women with polycystic ovary syndrome.
Katsikis I; Karkanaki A; Misichronis G; Delkos D; Kandaraki EA; Panidis D
Eur J Obstet Gynecol Reprod Biol; 2011 Jun; 156(2):181-5. PubMed ID: 21353371
[TBL] [Abstract][Full Text] [Related]
27. Comparison of fibrinolytic and metabolic system parameters in obese patients with polycystic ovary syndrome and women with simple obesity.
Słopień R; Lewandowski K; Kolacz E; Zawilska K; Warenik-Szymankiewicz A
Gynecol Endocrinol; 2006 Nov; 22(11):651-4. PubMed ID: 17145652
[TBL] [Abstract][Full Text] [Related]
28. The association of serum androgens and insulin resistance with fat distribution in polycystic ovary syndrome.
Yucel A; Noyan V; Sagsoz N
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):81-6. PubMed ID: 16337726
[TBL] [Abstract][Full Text] [Related]
29. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.
Barber TM; Wass JA; McCarthy MI; Franks S
Clin Endocrinol (Oxf); 2007 Apr; 66(4):513-7. PubMed ID: 17371468
[TBL] [Abstract][Full Text] [Related]
30. Mullerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics.
La Marca A; Orvieto R; Giulini S; Jasonni VM; Volpe A; De Leo V
Fertil Steril; 2004 Oct; 82(4):970-2. PubMed ID: 15482785
[TBL] [Abstract][Full Text] [Related]
31. Serum ghrelin level in women with polycystic ovary syndrome and its relationship with endocrine and metabolic parameters.
Mitkov M; Pehlivanov B; Orbetzova M
Gynecol Endocrinol; 2008 Nov; 24(11):625-30. PubMed ID: 19031219
[TBL] [Abstract][Full Text] [Related]
32. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
Kazerooni T; Dehghan-Kooshkghazi M
Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
[TBL] [Abstract][Full Text] [Related]
33. Association between serum adipocyte factor level and insulin resistance in polycystic ovarian syndrome.
Wang Q; Guo T; Tao Y; Wang Q; Song Y; Huang W
Gynecol Endocrinol; 2011 Nov; 27(11):931-4. PubMed ID: 21495802
[TBL] [Abstract][Full Text] [Related]
34. [Association of monocyte chemoattractant protein-1 and the clinical characteristics of polycystic ovary syndrome: analysis of 65 cases].
Hu WH; Qiao J; Li MZ
Zhonghua Yi Xue Za Zhi; 2007 Mar; 87(11):721-4. PubMed ID: 17565837
[TBL] [Abstract][Full Text] [Related]
35. [Activation and significance of the PI3K/Akt pathway in endometrium with polycystic ovary syndrome patients].
Zhang HY; Zhang YF; Han YK; Xue FX; Zhao XH; Zhang XL
Zhonghua Fu Chan Ke Za Zhi; 2012 Jan; 47(1):19-23. PubMed ID: 22455688
[TBL] [Abstract][Full Text] [Related]
36. Omental fat receptor interacting protein 140 mRNA expression in women with polycystic ovary syndrome.
Seow KM; Tsai YL; Juan CC; Huang LW; Hwang JL; Ho LT
Gynecol Obstet Invest; 2010; 69(1):51-6. PubMed ID: 19887821
[TBL] [Abstract][Full Text] [Related]
37. Impaired insulin action on granulosa-lutein cells in women with polycystic ovary syndrome and insulin resistance.
Fedorcsák P; Storeng R; Dale PO; Tanbo T; Abyholm T
Gynecol Endocrinol; 2000 Oct; 14(5):327-36. PubMed ID: 11109972
[TBL] [Abstract][Full Text] [Related]
38. [The effects of FSH,LH and insulin on steroids production by granulosa cells from polycystic ovaries syndrome].
Wang A; Lu C; Qiao J
Zhonghua Yi Xue Za Zhi; 1998 Nov; 78(11):830-2. PubMed ID: 11038778
[TBL] [Abstract][Full Text] [Related]
39. Serum resistin and adiponectin levels in young non-obese women with polycystic ovary syndrome.
Arikan S; Bahceci M; Tuzcu A; Kale E; Gökalp D
Gynecol Endocrinol; 2010 Mar; 26(3):161-6. PubMed ID: 20148738
[TBL] [Abstract][Full Text] [Related]
40. Adiponectin levels in adolescent girls with polycystic ovary syndrome (PCOS).
Pinhas-Hamiel O; Singer S; Pilpel N; Koren I; Boyko V; Hemi R; Pariente C; Kanety H
Clin Endocrinol (Oxf); 2009 Dec; 71(6):823-7. PubMed ID: 19389110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
